On February 21, the FDA announced that the shortage of semaglutide injection products has been resolved. Semaglutide has appeared on the FDA’s ...
Makers of copycat versions of Novo Nordisk's (NVO) popular weight-loss drug semaglutide, also known as Ozempic and Wegovy, ...
Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...
Compounders have filed a lawsuit against the FDA challenging its decision to remove Novo Nordisk's Wegovy and Ozempic from the shortage list. The lawsuit claims the FDA's actions are arbitrary, ...
Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...